Current role of allogeneic stem cell transplantation in breast cancer

Annals of Oncology

Volumn 18, Issue 10, 2007, Pages 1591-1593

  Carella, Angelo Michele ^a   Bregni, M ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b Faculty of Medicine   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; FLUDARABINE; IMMUNOGLOBULIN; MINOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; MYELOABLATIVE AGENT; TAXANE DERIVATIVE; THIOTEPA; TRASTUZUMAB;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; BONE LESION; BONE MARROW TRANSPLANTATION; BREAST CANCER; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; EDITORIAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HORMONAL THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; METASTASIS; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; RISK FACTOR; TREATMENT RESPONSE; WHOLE BODY RADIATION;

EID: 34848906810     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm342     Document Type: Editorial

References (18)

1. Eibl B, Schwaighofer H, Nachbaur D et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501-1508.
2. Ueno NT, Rondón G, Mirza NQ et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998; 16: 986-993.
3. Rizzieri DA, Long GD, Vredenburgh JJ et al. Non-myeloablative allogeneic transplantation using T depleted matched sibling peripheral blood stem cells. Blood 2001; 98: 420a (abstr 1764).
4. Or R, Ackerstein A, Nagler A et al. Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: A clinical pilot study. Cytokines Cell Mol Ther 1998; 4: 1-6.
5. Bregni M, Dodero A, Peccatori J et al. Nonmyeloablative oonditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234-4236.
6. Carella AM, Beltrami G, Lerma E et al. Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer. Cancer Treat Res 2002; 110: 101-112.
7. Ueno NT, Cheng YC, Rondón G et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829-3836.
8. Blaise D, Bay JO, Faucher C et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103: 435-441.
9. Bishop MR, Fowler DH, Marchigiani D et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004; 22: 3886-3892.
10. Childs RW, Clave E, Tisdale J et al. Successful treatment of metastatic renal-cell carcinoma with a nonmyeloablative allogeneic peripheral blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect. J Clin Oncol 1999; 17: 2044-2049.
11. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
12. Ben-Yosef R, Or R, Nagler A, Slavin S. Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukemia. Lancet 1996; 348: 1242-1243.
13. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
14. Morecki S, Moshel Y, Gelfend Y et al. Induction at graft vs tumor effect in a murine model of mammary adenocarcinoma. Int J Cancer 1997; 71: 59-63.
15. Morecki S, Yacovlev E, Gelfand Y et al. Cell therapy with pre-immunized-effector cells mismatched for-minor histocompatible antigens, in the treatment of a murine mammary carcinoma. J Immunother 2001; 24: 114-121.
16. Marijt W, Heemskerk MH, Kloosterboer FM et al: Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100: 2742-2747.
17. Carella AM, Beltrami G, Corsetti MT et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005; 366: 318-320.
18. Piccart-Gebhart MJ. Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: What we know and what we still need to learn. Eur J Cancer 2006; 42: 1715-1719.